- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07230249
Поддержка в Telegram Messenger для отказа от курения после инфаркта (TELEGRAM-MI)
Эффективность поведенческого вмешательства, проводимого через мессенджер Telegram, по отказу от курения у пациентов после инфаркта миокарда: рандомизированное контролируемое исследование TELEGRAM-MI
This randomized controlled trial will evaluate whether a 6-month behavioral intervention delivered via Telegram messenger increases smoking cessation rates in patients after myocardial infarction (MI).
Adult smokers hospitalized with acute MI who regularly use Telegram will be randomly assigned to either:
- INTERVENTION GROUP: Standard care plus a 6-month Telegram chatbot program providing personalized motivational messages, cognitive-behavioral techniques for craving management, and relapse prevention support.
- CONTROL GROUP: Standard care (routine physician advice to quit smoking) plus basic surveys via Telegram without therapeutic content.
The primary outcome is 30-day point prevalence abstinence at 6 months, verified by blinded telephone interview with participant and corroborating report from a close relative. Secondary outcomes include changes in cigarette consumption, nicotine dependence, motivation, and intervention engagement metrics.
This study addresses the critical gap in smoking cessation support after hospital discharge and could provide evidence for a scalable digital health solution in cardiac secondary prevention.
Обзор исследования
Статус
Подробное описание
The TELEGRAM-MI trial is a multicenter, randomized, controlled, assessor-blinded superiority study testing a digital behavioral intervention for smoking cessation in post-myocardial infarction patients.
BACKGROUND: Smoking cessation is the most effective modifiable risk factor for reducing mortality after MI, yet long-term abstinence remains challenging due to limited sustained support. Digital interventions using popular messaging platforms offer a scalable solution to bridge the post-discharge support gap.
OBJECTIVES:
Primary: To determine if a 6-month Telegram chatbot intervention increases 30-day point prevalence abstinence rates at 6 months compared to standard care alone.
Secondary: To examine associations between baseline characteristics (nicotine dependence, motivation), engagement metrics, and cessation success; and to assess intervention acceptability.
METHODS: Approximately 142 participants will be recruited from inpatient cardiology departments. After providing informed consent, participants will be randomized 1:1 via the chatbot to either the intervention group (standard care plus 6-month behavioral support) or control group (standard care plus data collection only). The intervention incorporates evidence-based techniques including motivational messaging, cognitive-behavioral strategies, and relapse prevention protocols.
OUTCOMES: The primary outcome is biochemically unverified 30-day point prevalence abstinence at 6 months, assessed via blinded telephone interview with participant and relative verification. Secondary outcomes include various smoking behavior metrics collected through the chatbot platform.
ANALYSIS: Primary analysis will follow intention-to-treat principles, with missing data imputed as smoking. Statistical analyses will include chi-square tests for primary outcome and regression models for secondary outcomes.
POTENTIAL IMPACT: If effective, this intervention represents a readily implementable, low-cost strategy to enhance secondary prevention in cardiac patients.
Тип исследования
Регистрация (Оцененный)
Фаза
- Непригодный
Контакты и местонахождение
Контакты исследования
- Имя: Mikhail A. Kuznetsov, MD
- Номер телефона: +79170610352
- Электронная почта: mihkuzn@gmail.com
Учебное резервное копирование контактов
- Имя: Dmitry V. Sergeev, PhD
- Номер телефона: +79802128785
- Электронная почта: ser.dmitry.v@gmail.com
Места учебы
-
-
-
Ulyanovsk, Россия
- Рекрутинг
- Ulyanovsk Regional Clinical Hospital
-
Контакт:
- Administration of Clinical Hospital
- Номер телефона: +7 8422 32 32 71
- Электронная почта: uokb@med.ulgov.ru
-
-
Ulyanovsk Oblast
-
Ulyanovsk, Ulyanovsk Oblast, Россия, 432000
- Еще не набирают
- Ulyanovsk Regional Clinical Hospital
-
Контакт:
- Mikhail A. Kuznetsov, MD
- Номер телефона: +79170610352
- Электронная почта: mihkuzn@gmail.com
-
Контакт:
- Dmitry V. Sergeev, PhD
- Номер телефона: +79802128785
- Электронная почта: ser.dmitry.v@gmail.com
-
Главный следователь:
- Mikhail A. Kuznetsov, MD
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Willing and able to provide written informed consent.
- Age 18 years or older.
- Hospitalization with a confirmed diagnosis of acute myocardial infarction (MI), including both ST-elevation MI (STEMI) and non-ST-elevation MI (NSTEMI), enrolment occurring either during index hospitalization or within 1 month post-MI at an outpatient visit
- Current smoker at the time of index MI: self-reported smoking of at least one cigarette per day in the month prior to hospitalization.
- Regular user of the Telegram messenger application (app installed on a personal smartphone).
- Possession of a smartphone with internet access and a valid phone number.
- Ability and willingness to provide contact information for a close relative or cohabiting person who can verify smoking status at follow-up.
Exclusion Criteria:
- Smoking cessation more than 1 month prior to the index MI hospitalization.
- Physical or cognitive impairment that prevents the use of a smartphone (e.g., severe visual/hearing impairment, inability to read or respond to messages).
- Inability to read and understand the Russian language fluently.
- Comorbid condition with a life expectancy of less than 1 year.
- Active severe mental illness (e.g., psychosis, severe untreated depression) that would impede understanding of the protocol or adherence.
- Unwillingness or inability to provide contact details for a close relative for outcome verification.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Одинокий
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Telegram Bot Intervention Group
Participants receive standard care PLUS the 6-month behavioral intervention delivered via the Telegram chatbot. |
A 6-month behavioral intervention delivered via a Telegram chatbot. The intervention includes personalized daily motivational messages, cognitive-behavioral techniques for craving management, access to an SOS/craving support button, weekly check-ins, and relapse prevention protocols. Content is tailored based on user responses to questionnaires (Fagerström Test, Importance/Confidence scales) and engagement metrics. |
|
Другой: Standard Care Control Group
Participants receive standard care only. They are connected to the Telegram bot but only complete baseline and follow-up surveys without receiving any active smoking cessation content. |
Routine physician advice to quit smoking provided upon hospital discharge. This represents the current standard of care in the participating clinical centers. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
30-day point prevalence abstinence (PPA)
Временное ограничение: 6 months
|
Proportion of participants who report abstinence from smoking for the past 30 days or more, verified by both participant self-report AND corroborating report from a close relative or cohabiting person during a telephone interview conducted by a blinded assessor. A positive outcome is recorded ONLY if both sources confirm abstinence. Participants with missing data (e.g., lost to follow-up) will be considered smokers in the primary analysis (intention-to-treat). |
6 months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
7-day point prevalence abstinence (7-day PPA)
Временное ограничение: 1 month and 3 months
|
Proportion of participants who report abstinence from smoking for the past 7 days. Assessed via the Telegram bot. |
1 month and 3 months
|
|
Change in cigarette consumption
Временное ограничение: Baseline, 1 month, 3 months, and 6 months
|
Change from baseline in the self-reported number of cigarettes smoked per day. Assessed via the Telegram bot. |
Baseline, 1 month, 3 months, and 6 months
|
|
Score on the Fagerström Test for Nicotine Dependence (FTND)
Временное ограничение: Baseline and 6 months
|
Change in nicotine dependence measured by the FTND questionnaire (score range 0-10, higher scores indicate greater dependence). Assessed via the Telegram bot. |
Baseline and 6 months
|
|
Motivation to quit (Importance and Confidence Scales)
Временное ограничение: Baseline and 6 months
|
Scores on self-rated scales (0-10) for the importance of quitting and confidence in the ability to quit. Assessed via the Telegram bot. |
Baseline and 6 months
|
|
Participant engagement with the Telegram bot
Временное ограничение: 6 months
|
Composite measure of engagement (dose) including: proportion of completed weekly check-ins, proportion of opened messages, number of SOS/craving button uses, number of active weeks. Metrics are automatically logged by the bot. |
6 months
|
|
Intervention acceptability and satisfaction
Временное ограничение: 6 months
|
Total score on a custom acceptability and satisfaction questionnaire (5-12 items) completed by participants in the intervention group via the Telegram bot. Higher scores indicate higher satisfaction. |
6 months
|
|
Time to first relapse
Временное ограничение: 6 months
|
Number of days from randomization to the first self-reported relapse (lapse) event. Assessed via continuous monitoring through the bot's check-in system. |
6 months
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Mikhail Kuznetsov, MD, Ulyanovsk Regional Clinical Hospital
- Директор по исследованиям: Dmitry Sergeev, PhD, ITMO University
- Директор по исследованиям: Artemiy Okhotin, MPH, ITMO University
Публикации и полезные ссылки
Общие публикации
- Olano-Espinosa E, Avila-Tomas JF, Minue-Lorenzo C, Matilla-Pardo B, Serrano Serrano ME, Martinez-Suberviola FJ, Gil-Conesa M, Del Cura-Gonzalez I; Dejal@ Group. Effectiveness of a Conversational Chatbot (Dejal@bot) for the Adult Population to Quit Smoking: Pragmatic, Multicenter, Controlled, Randomized Clinical Trial in Primary Care. JMIR Mhealth Uhealth. 2022 Jun 27;10(6):e34273. doi: 10.2196/34273.
- Bricker JB, Sullivan BM, Mull KE, Lavista-Ferres J, Santiago-Torres M. Efficacy of a conversational chatbot for cigarette smoking cessation: Protocol of the QuitBot full-scale randomized controlled trial. Contemp Clin Trials. 2024 Dec;147:107727. doi: 10.1016/j.cct.2024.107727. Epub 2024 Oct 28.
- Hayrumyan V, Harutyunyan A, Harutyunyan T. Smoking cessation after myocardial infarction: Findings from a cross-sectional survey in Armenia. Tob Prev Cessat. 2023 Dec 11;9:36. doi: 10.18332/tpc/174359. eCollection 2023.
- Gerber Y, Rosen LJ, Goldbourt U, Benyamini Y, Drory Y; Israel Study Group on First Acute Myocardial Infarction. Smoking status and long-term survival after first acute myocardial infarction a population-based cohort study. J Am Coll Cardiol. 2009 Dec 15;54(25):2382-7. doi: 10.1016/j.jacc.2009.09.020.
- Leosdottir M, Warjerstam S, Michelsen HO, Schlyter M, Hag E, Wallert J, Larsson M. Improving smoking cessation after myocardial infarction by systematically implementing evidence-based treatment methods. Sci Rep. 2022 Jan 12;12(1):642. doi: 10.1038/s41598-021-04634-5.
- Wilson K, Gibson N, Willan A, Cook D. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med. 2000 Apr 10;160(7):939-44. doi: 10.1001/archinte.160.7.939.
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Сосудистые заболевания
- Сердечно-сосудистые заболевания
- Патологические процессы
- Сердечные заболевания
- Инфаркт
- Некроз
- Ишемия миокарда
- Ишемия
- Патологические состояния, признаки и симптомы
- Поведение
- Поведение в отношении здоровья
- Инфаркт миокарда
- Отказ от курения
- Употребление табака
- Администрация медицинских услуг
- Качество, доступ и оценка здравоохранения
- Качество здравоохранения
- Индикаторы качества, здравоохранение
- Стандарт ухода
Другие идентификационные номера исследования
- TELEGRAM-MI
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
All individual participant data collected during the trial, after de-identification, will be shared. This includes demographic data, smoking history, questionnaire responses (Fagerström Test, Importance/Confidence scales), intervention engagement metrics, and primary/secondary outcome data.
Сроки обмена IPD
Beginning 12 months after main results publication and ending 5 years after publication. Data will be available for this period.
Критерии совместного доступа к IPD
Data will be available to researchers who provide a methodologically sound research proposal approved by an independent review committee. Proposals should be directed to the corresponding author. Requestors will need to sign a data access agreement specifying the purpose of analysis, commitment to secure data handling, and agreement not to attempt re-identification of participants.
Совместное использование IPD Поддерживающий тип информации
- STUDY_PROTOCOL
- САП
- МКФ
- АНАЛИТИЧЕСКИЙ_КОД
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .